Aytu Biopharma (AYTU) Cost of Revenue (2014 - 2026)

Aytu Biopharma (AYTU) has reported Cost of Revenue for 13 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 14.77% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $19.9 million, a 3.77% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 27.42% from the prior year.
• Cost of Revenue was $4.8 million for Q1 2026 at Aytu Biopharma, down from $5.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $12.6 million in Q2 2022 and troughed at $3.5 million in Q2 2024.
• A 5-year average of $6.9 million and a median of $5.4 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue sank 70.9% in 2024 and jumped 54.09% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $9.0 million in 2022, then plunged by 53.87% to $4.1 million in 2023, then jumped by 31.12% to $5.4 million in 2024, then rose by 1.95% to $5.5 million in 2025, then fell by 13.16% to $4.8 million in 2026.
• The last three Cost of Revenue figures came in at $4.8 million (Q1 2026), $5.5 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.